Unaudited Financial Results for the Quarter and Nine Months Ended on December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals reported weak Q3FY26 results with standalone revenue from operations falling 38.5% YoY to ₹41.41 crore, though largely flat sequentially versus ₹41.70 crore in Q2FY26. Standalone PAT stood at ₹1.95 crore vs ₹6.51 crore in Q3FY25, while EBITDA margin (excluding other income) compressed to ~8% from 12% a year ago. On a consolidated basis, the company posted a net loss of ₹9.63 crore in Q3 and ₹19.15 crore for 9M FY26, mainly due to ongoing R&D and operational investments at subsidiary Innoxel Lifesciences. Management attributed the standalone weakness to timing-related deferment of institutional purchase orders rather than a demand issue, and disclosed an order book of ₹303 crore for the first time, with most execution expected in H1FY27. The statutory auditor (Shah Mehta & Bakshi) issued an unmodified limited review conclusion on both standalone and consolidated results.
Negative near-term for the stock given the sharp YoY revenue decline and consolidated losses, but the ₹303 crore order book disclosure, expected Q4FY26 revenue recovery to ₹50–55 crore, and a clean auditor opinion provide some forward-looking comfort for patient investors.